Enfuego Therapeutics Inc.
Publicly observedPittsboro, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Pittsboro | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Enfuego Therapeutics Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | N4XYELPNM224 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant14 Sept 2026Publicly observed
NIH SBIR/STTR award: Overcoming Adaptive KRAS Inhibitor Resistance with Ligand-Directed KRAS G12V-panTEAD Chimeras
USD 311,734.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant5 Jul 2023Publicly observed
NIH SBIR/STTR award: Ligand-Directed KRAS G12V Mutant-Specific Therapeutics
USD 919,020.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.